myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive

doi:10.1182/blood-2009-01-198093Prepublished online May 21, 2009;2009 114: 1166-1173€€€€Annick Bessems, Peter De Porre, Angela J. Howes and for the FIGHT-AML-301 InvestigatorsRobak, Nuriet K. Khuageva, Anatoly K. Golenkov, Elena Tothova, Lars Mollgard, Youn C. Park, Johan Maertens, Maria-Belen Vidriales, Herve Dombret, Xavier Thomas, Alan K. Burnett, TadeuszDominique Bordessoule, Tamas Masszi, Gert J. Ossenkoppele, Julia A. Alexeeva, Gernot Beutel, Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W. Jedrzejczak, Joseph M. Brandwein,€

[1]  E. Estey,et al.  Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome , 2008, Clinical Cancer Research.

[2]  Bob Löwenberg,et al.  A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. , 2007, Blood.

[3]  G. Mufti,et al.  A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome , 2007 .

[4]  E. Estey,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[6]  P. Greenberg,et al.  A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. , 2007, Blood.

[7]  A. Bordoni,et al.  Epidemiology of hematological malignancies. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[9]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[10]  C. Earle,et al.  Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly , 2005, Drugs & aging.

[11]  M. Litzow.  The therapy of relapsed acute leukaemia in adults. , 2004, Blood reviews.

[12]  M. Schaich.  Elderly acute myeloid leukemia: patients are not all the same. , 2004, Haematologica.

[13]  M. Fey.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Stone,et al.  The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.

[15]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[16]  G. Jackson,et al.  Acute Myeloid Leukaemia , 2002, Drugs & aging.

[17]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[18]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[19]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[20]  E. Estey.  How I treat older patients with AML. , 2000, Blood.

[21]  C. Willman,et al.  Acute myelogenous leukemia and aging. Clinical interactions. , 2000, Hematology/oncology clinics of North America.

[22]  T. Hamblin,et al.  Colony-Stimulating Factors in the Treatment of Older Patients with Acute Myelogenous Leukaemia , 1999, Drugs & aging.

[23]  W. Hiddemann,et al.  Management of acute myeloid leukemia in elderly patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[25]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.